Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologySummaCare Alzheimer Biomarker Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Alzheimer's Disease Biomarkers Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity for cerebrospinal fluid biomarker testing used to evaluate initiation of amyloid beta-targeting therapy in commercial and Medicare members with mild cognitive impairment or mild dementia due to Alzheimer disease; plasma and other specified biomarker tests are identified as experimental, investigational, or unproven.

    Policy Summary
    PayerSummaCare
    PolicyAlzheimer's Disease Biomarkers Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 11, 2026
    Last ReviewJun 11, 2026
    Next Review DateN/A
    Key ActionObtain authorization before performing qualifying CSF amyloid beta and tau biomarker testing to evaluate initiation of amyloid beta-targeting therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Commercial + MedicarePlans covered
    CSFCovered specimen type

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Covered CSF assays
    PlasmaNot covered specimen type
    4Investigational biomarker codes

    Coverage Criteria

    Medically Necessary CSF Biomarker Testing

    Covered when the following medical-necessity criterion is met:

    CSF biomarker testing of amyloid beta peptides and tau protein is medically necessary for evaluating whether to initiate amyloid beta-targeting therapy in an individual with mild cognitive impairment or mild dementia due to Alzheimer disease.

    When the criterion is met, covered CPT codes include 0445U (β-amyloid Abeta42 and phospho tau 181P [pTau181], ECLIA, cerebrospinal fluid, ratio reported as positive or negative for amyloid pathology) and 0459U (β-amyloid Abeta42 and total tau [tTau], ECLIA, cerebrospinal fluid, ratio reported as positive or negative for amyloid pathology).

    Plasma Alzheimer disease biomarker testing is not covered. The following plasma or whole-blood tests are considered experimental, investigational, or unproven for the diagnosis and management of members with Alzheimer disease and related dementia because of insufficient evidence that they improve health outcomes or medical management: 0568U (neurology/dementia beta amyloid, phosphorylated tau protein, neurofilament light chain, and glial fibrillary acidic protein by ultra-high-sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology; LucentAD™ Complete, Quanterix Corporation) and 0570U (neurology/traumatic brain injury analysis of glial fibrillary acidic protein and ubiquitin carboxyl-terminal hydrolase L1 by immunoassay, whole blood or plasma, with individual components and an overall elevated or non-elevated result; i-STAT TBI, Abbott Point of Care). There are currently no applicable NCD or LCD per CMS.

    Biomarkers may be measured in fluids such as blood, urine, saliva, serum, and plasma; however, plasma and whole-blood Alzheimer disease biomarker testing is not covered or is considered experimental, investigational, or unproven as specified above.

    Biomarker measurements billed under CPT codes 82233 (beta-amyloid 1-40 [Abeta40]), 82234 (beta-amyloid 1-42 [Abeta42]), 84393 (phosphorylated tau), and 84394 (total tau [tTau]) are considered investigational for the diagnosis and management of Alzheimer disease because adequate medical evidence has not established that these measurements are clinically useful.

    Coding

    CPT codes covered if criteria are metCPTCovered
    0445Uβ-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
    0459Uβ-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology
    82233Beta-amyloid; 1-40 (Abeta 40)
    82234Beta-amyloid; 1-42 (Abeta 42)
    84393Tau, phosphorylated
    84394Tau, total (tTau)
    Not covered or investigational biomarker testingCPTExperimental
    0568UNeurology (dementia), beta amyloid, tau protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology. LucentAD Complete, Quanterix Corporation.
    0570UNeurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl terminal hydrolase L1 (UCHL1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison. i-STAT TBI, Abbott Point of Care.
    82233Beta-amyloid; 1-40 (Abeta 40)
    82234Beta-amyloid; 1-42 (Abeta 42)
    84393Tau, phosphorylated
    84394Tau, total (tTau)
    CPT codes not coveredCPTNot Covered
    0568UNeurology (dementia), beta amyloid, tau protein phosphorylated at residue (eg, pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), by ultra-high sensitivity molecule array detection, plasma, algorithm reported as positive, intermediate, or negative for Alzheimer pathology. LucentAD Complete, Quanterix Corporation.
    0570UNeurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl terminal hydrolase L1 (UCHL1), immunoassay, whole blood or plasma, individual components reported with the overall result of elevated or non-elevated based on threshold comparison. i-STAT TBI, Abbott Point of Care.

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for qualifying cerebrospinal fluid (CSF) biomarker testing of amyloid beta peptides and tau protein when evaluating initiation of amyloid beta-targeting therapy.

    • Covered when criteria are met: 0445U and 0459U
    • 82233: Beta-amyloid; 1-40 (Abeta 40)
    • 82234: Beta-amyloid; 1-42 (Abeta 42)
    • 84393: Tau, phosphorylated
    • 84394: Tau, total (tTau)
    Denial Risk

    Uncovered or Investigational Biomarker Testing

    Plasma biomarker testing is not covered. CSF or plasma biomarkers identified as experimental, investigational, or unproven may be denied because of insufficient evidence of improved health outcomes or medical management.

    Background

    Alzheimer disease is the most common form of dementia. It involves cognitive decline severe enough to interfere with activities of daily living, generally lasting at least six months and occurring in adulthood. Disease progression is associated with biomarkers that may assist with diagnosis and monitoring. This policy focuses on cerebrospinal fluid amyloid beta and tau testing when evaluating eligibility to initiate amyloid beta-targeting therapy.

    Definitions

    Alzheimer disease
    DefinitionLoss of mental ability severe enough to interfere with normal activities of daily living.
    Duration and onsetThe impairment lasts at least six months, occurs in adulthood, and is not present from birth.
    Cognitive changesThe disease is marked by decline in cognitive functions such as remembering, reasoning, and planning.
    Mild cognitive impairment
    DefinitionA clinical state involving cognitive impairment that is more than expected for age.
    Daily functioningThe impairment does not necessarily substantially interfere with independent daily functioning.

    Covered Indications

    Not Covered

    The following are not covered: plasma Alzheimer disease biomarker testing; plasma or whole-blood tests 0568U and 0570U; and biomarker measurements 82233, 82234, 84393, and 84394 when used for Alzheimer disease diagnosis or management as investigational testing.

    Policy Summary
    PayerSummaCare
    PolicyAlzheimer's Disease Biomarkers Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 11, 2026
    Last ReviewJun 11, 2026
    Next Review DateN/A
    Key ActionObtain authorization before performing qualifying CSF amyloid beta and tau biomarker testing to evaluate initiation of amyloid beta-targeting therapy.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsBackgroundDefinitionsCovered IndicationsNot Covered
    • Not covered: 0568U, plasma beta amyloid, phosphorylated tau, neurofilament light chain, and GFAP testing (LucentAD Complete)
    • Not covered: 0570U, whole blood or plasma GFAP and UCHL1 testing (i-STAT TBI)
    • The policy states that measurement of 82233, 82234, 84393, and 84394 is investigational for Alzheimer disease diagnosis and management because clinical usefulness is not adequately established.
    • Biomarkers measured in blood, urine, saliva, serum, or plasma may be considered investigational when used for Alzheimer disease diagnosis or management.
    Denial Risk

    Indication Does Not Meet Authorization Criteria

    Authorization criteria are limited to CSF amyloid beta peptide and tau protein testing to evaluate initiation of amyloid beta-targeting therapy in the specified clinical population. Testing for other indications does not meet authorization criteria.

    • The member must have mild cognitive impairment or mild dementia due to Alzheimer disease.
    • The requested testing must evaluate initiation of amyloid beta-targeting therapy.
    • Testing for diagnosis or management outside this indication is not authorized under this policy.
    Distinction from dementia
    Unlike dementia, mild cognitive impairment may be present without substantial interference with independent daily activities.
    Mild dementia due to Alzheimer disease
    DefinitionA less advanced stage of dementia due to Alzheimer disease.
    Cognitive impairmentCognitive impairment is present as part of the condition.
    Disease severityThe disease remains mild in severity.